Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Coronary Microvascular Dysfunction (CMD)

Go Beyond The Angiogram To Get To The Root Cause Of Persistent Angina

Coronary Microvascular Dysfunction (CMD)

Angiography Doesn't Tell You The Whole Story

Approximately 112 million people globally are affected by angina and undergo coronary angiography, the primary diagnostic test for angina.1

Too often patients with ischemia and no obstructive coronary artery disease (INOCA) on angiography — remain undiagnosed.2

Coronary Microvascular Dysfunction (CMD)3 is defined as impaired blood flow to the microcirculation. A clear diagnosis and optimized treatment plan can improve outcomes for these patients at high risk for major adverse events (MACE).4

up to 50%

How A Microvascular Dysfunction Diagnosis Benefits Patients

The CorMicA (CORonary MICrovascular Angina) study revealed that patients may benefit when CMD is accurately diagnosed and appropriately treated:4

  • Adequate evaluation and optimal treatment of patients who have INOCA can relieve patient symptoms, improve Quality of Life (QoL) and may reduce healthcare costs.4,6
  • An accurate CMD diagnosis can help reduce healthcare resource consumption,7 resulting in lower costs for hospitals and patients8 with a savings from $2,100 (Netherlands) to $7,300 (U.S.) per hospitalization avoided (2017 costs).9
  • An economic analysis of the CorMicA study showed that a comprehensive physiology assessment is cost-effective compared to standard care (medical therapy and cardiac rehabilitation care) at 1-year follow-up.10
27 improvement in angina severity in 1 year

Challenges Diagnosing the Underlying Causes Of Chest Pain

Ischemic heart disease continues to be the leading cause of death globally.11 Yet chest pain—while often ischemic in nature—could have many etiologies, as illustrated.3 When chest pain is caused by ischemia, proper management depends on accurately identifying and treating the underlying cause of angina.

Chest Pain

STRUCTURAL CAUSES7
  • In-stent restenosis
  • Stent thrombosis
  • Progression of atherosclerotic disease in other segments
  • Incomplete revascularization
  • Diffuse atherosclerotic disease without focal stenosis
  • Presence of myocardial bridges
FUNCTIONAL CAUSES7
  • Epicardial vasospasm
  • Coronary microvascular dysfunction
  • Stent-related mechanical stretch of the arterial wall

The Common Diagnosis Of INOCA

Only 41% of patients assessed for angina are found to have obstructive chronic Coronary Artery Disease.13 The majority, 59% of patients, assessed for angina are found to have no angiographic abnormalities, but still have symptoms of a coronary disorder.4,5

INOCA Diagnosis Chart

20-30% of patients experience recurrent angina in 1 year after percutaneous coronary intervention (PCI).12

20-30% of patients experience recurrent angina

Without a clear diagnosis and treatment, patients may experience recurrent hospitalizations, poor functional health, and adverse cardiovascular outcomes.7

*According to the Seattle Angina Questionnaire score.
 

References

  1. Kunadian, V. et al. An EAPCI Expert Consensus Document on Ischaemic with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal. 2020; 0:1-21.
  2. Jespersen, L. et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734-744. doi:10.1093/eurheartj/ehr331.
  3. Marinescu, MA. et al. Coronary microvascular dysfunction and microvascular angina: a systematic review of therapies. JACC Cardiovasc Imaging. 2015;8:210-220.
  4. Ford, TJ. et al. 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Intv. 2020; 13:33-45.
  5. Patel, MR. et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886-895. doi:10.1056/NEJMoa0907272.
  6. Heggie, R. et al. Stratified medicine using invasive coronary function testing in angina: a cost-effectiveness analysis of the British Heart Foundation CorMicA trial. IJC. 2021; doi: 10.1016/j.ijcard.2021.05.016.
  7. Lee, B. et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131:1054–1060.
  8. Reriani, M. et al. Coronary endothelial function testing may improve long-term quality of life in subjects with microvascular coronary endothelial dysfunction. Open Heart. 2019;6:e000870.
  9. Omerovic, E. et al. FFR-Guided Complete Revascularization During Primary Angioplasty: Effects on Societal Costs. EuroPCR 2017.
  10. Heggie, R. et al. A cost-effectiveness analysis of the BHF CorMicA Trial. Interventional Journal of Cardiology 2021. Doi:10.1016/j.ijcard.2021.05.016.
  11. Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459-544.
  12. Jeremias, A. Post-PCI Physiology: Insights from DEFINE PCI and other Studies Speaker Presentation. TCT 2019.
  13. Maas, A. et al. Microvascular angina: diagnosis, assessment, and treatment. EMJ Int Cardiol. 2019; 7[Suppl 1]2-17.

 

MAT-2302510 v1.0

Important Safety Information

Coroventis‡ CoroFlow‡ Cardiovascular System

rx-only-logo

Indications: CoroFlow‡ is indicated to provide hemodynamic information for use in the diagnosis of patients with cardiovascular diseases.

CoroFlow‡ is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display various physiological parameters based on the output from one or more measuring devices.

Contraindications: The system has no patient alarm functions. Do not use for cardiac/vital signs monitoring.

Warnings:

  • If CoroFlow‡ is used together with 3rd party infusion catheters for assessment of Absolute Flow and Resistance, ensure that the maximum infusion rate per manufacturers instruction is not exceeded or vessel injury may occur.
  • Do not use the CoroFlow‡ Cardiovascular System if there is reason to believe the system's security has been compromised or if the system was unaccounted for a period of time (i.e. misappropriated, modified or tampered with).
  • Do not leave the CoroFlow‡ Cardiovascular System unattended when logged in as a PC Administrator.
  • To protect the privacy and security of sensitive information, including electronic protected health information (EPHI), and to protect the integrity of the system itself, the system should be located in a physically secure, access-controlled environment.
  • To protect the privacy and security of sensitive information, including electronic protected health information (EPHI), the PC on to which CoroFlow‡ is installed must be configured according to the Installation Instructions in this manual. Failure to configure the PC correctly may result in increased risk for unauthorized release of protected health information. Windows settings include:
    • Activation and configuration of restricted user Access
    • Activation of Windows Firewall and blocking of network connections
    • Activation of Windows Bitlocker drive encryption
    • Activation of Windows Secure Boot
    • Activation of Windows Anti-Virus scanning and ransomware protection. Ensure CoroFlow‡ is added in the list of trusted applications.
    • Activation of Windows update
    • Disable unused interfaces
  • Use of this equipment adjacent to or stacked with other equipment should be avoided because it could result in improper operation. If such use is necessary, this equipment and the other equipment should be observed to verify that they are operating normally.
  • Use of accessories, transducers and cables other than those specified or provided by Coroventis‡ could result in increased electromagnetic emissions or decreased electromagnetic immunity of this equipment and result in improper operation.
  • Portable RF communications equipment (including peripherals such as antenna cables and external antennas) should be used no closer than 30 cm (12 inches) to any part of CoroFlow‡, including cables specified by Coroventis‡. Otherwise, degradation of the performance of this equipment could result.

 

Precautions:

  • The PC and CoroHub‡ shall not be placed within the patient environment (1.5 m from patient).
  • For operation of other devices used in conjunction with CoroFlow‡ consult the IFU for each of these devices for details on indication, handling and safety information.
  • It is recommended to ensure local routines for data backup of stored recordings. CoroFlow‡ does not create backup of stored data.
  • Always check minimum performance requirement on PC to ensure compatibility with CoroFlow‡.
  • It is recommended to install CoroFlow‡ on a PC with backup battery to avoid interruption in case of power failure.
  • Always manually review and confirm valid cursor positions and detected heart beats.
  • Ensure that Pa and Pd pressure waveforms are aligned in phase and offset after equalization, or indices can be mis-calculated.
  • Confirm that the correct Wi-Box is selected by manually matching the Wi-Box ID number with the Wi-Box in the lab.
  • Changing parameter settings outside of default values may affect measurement performance, only for research purposes.
  • Only to be used by healthcare professionals.
  • Using a network location to store data may cause previously unidentified risks if the network malfunctions.
  • No modification or tampering with CoroFlow‡ is permitted.
  • CoroFlow‡, including accessories and components, shall not be used if it has been subject to damage.
  • The assembly of medical electrical systems and modifications during the actual service life require evaluation to the requirements according to IEC 60601-1 standard series.
  • CoroHub‡ does not have any serviceable parts and require no field maintenance. No modification or tampering with CoroHub‡ is permitted.
  • CoroHub‡ shall not be immersed in liquid.
  • CoroHub‡ shall not be used if it has been subject to damage.
  • PPG values may be non-unique and different combinations or focal/diffuse disease may result in the same PPG value.
  • Direct connection to a non-secure network, like the internet, may interfere with correct operation and/or result in inappropriate access to patient information. Furthermore, it should be noted that reconfiguring a used network may lead to inability to import patient as well as export examination data, ultimately leading to a risk of loss of patient and examination data. To avoid this problem Coroventis‡ recommends verifying network settings in the system setup after each change. The same caution is relevant regarding connection to DICOM.
  • Always confirm valid pressure tracings, marker positions and selected beats.
  • Resetting CoroHub‡ will reset PressureWire connections and Zeroing/Equalization parameters.

MAT-2007904 v4.0

PressureWire™ X Guidewire

rx-only-logo

INDICATIONS

The PressureWire™ X Guidewire is indicated to direct a catheter through a blood vessel and to measure physiological parameters in the heart and in the coronary and peripheral blood vessels. Physiological parameters include blood pressure. The PressureWire™ X Guidewire can also measure blood temperature.

CONTRAINDICATIONS

PressureWire™ X Guidewire is contraindicated for use in the cerebral vasculature.

POTENTIAL ADVERSE EVENTS               

Potential adverse events which may be encountered during all catheterization procedures include, but are not limited to:

  • Bleeding 
  • Hypotension / hypertension 
  • Chest pain 
  • Coronary / peripheral vascular injury 
    • Vascular dissection  
    • Perforation of vessels  
    • Stenosis  
    • Pseudoaneurysm 
  • Vasoconstriction 
  • Myocardial ischemia, tissue hypoxia 
  • Myocardial infarction 
  • Organ injury 
  • Thrombosis 
  • Death 
  • Arrhythmias 
  • Cardiac tamponade / pericardial effusion 
  • Bronchospasm (adenosine related) 
  • Prolonged procedure 
  • Foreign body in patient 
  • Urgent revascularization 
  • Congestive heart failure 
  • Embolus 
  • Local and / or systemic infection 
  • Device failures  
  • Hypersensitivity/ allergic reaction to device materials, medications or contrast 

In addition, this device has a coating containing Polyethylene Glycol (PEG); potential allergic reactions (anaphylaxis) may occur during the interventional procedure if the patient is allergic to PEG.

WARNINGS

  • The PressureWire™ X Guidewire must not be modified in any way by the customer. Making modifications may interfere with correct operation and will void product warranties. See your Abbott Technical Service representative for more information.
  • Note the product “Use-by-date” on the package.
  • The PressureWire™ X Guidewire is supplied sterile. Discard the guidewire if the pouch is opened or damaged, compromising the sterile barrier. The guidewire is designed for single use only and shall not be reused or resterilized. Adverse effects of using a non-sterile or resterilized guidewire may include, but are not limited to:
    • Local and / or systemic infection
    • Mechanical damage
    • Inaccurate readings
  • Observe all guidewire movements. Whenever the guidewire is moved or torqued, the tip movement should be examined under fluoroscopy. Never push, withdraw,
    or torque the guidewire if it meets resistance or without observing corresponding movement of the tip; otherwise, vessel/ventricle trauma may occur.
  • Torquing or excessive manipulation of the guidewire in a sharp bend, against resistance, or repeated attempts to cross a total vessel occlusion may:
    • Cause dissection or perforation of blood vessels
    • Cause vessel spasm
    • Damage and / or fracture the guidewire
  • When introducing the guidewire, flush the catheter and administer anticoagulation as for a standard catheterization procedure or clotting may occur.
  • Do not use the guidewire in the ventricles if the patient has a prosthetic mechanical or biological valve. It may result in damage to both the prosthesis and the guidewire, which may cause injury or death.
  • Use of the PressureWire™ X Guidewire in conjunction with interventional devices with a short rapid exchange may result in a folded or fractured guidewire.
  • High frequency surgical devices must not be used on a patient at the same time as the guidewire.
  • The safety and effectiveness of the coated device have not been established, or are unknown, in vascular regions other than those specifically indicated.
  • Failure to abide by the warnings in this Instructions for Use might result in damage to the device coating, which may necessitate intervention or result in serious adverse events.

PRECAUTIONS

  • The PressureWire™ X Guidewire is a delicate instrument and should be handled carefully.
  • Make sure that the PressureWire™ X Guidewire transmitter is kept dry to ensure accurate pressure and/or temperature readings. Inaccurate readings or a wet transmitter may necessitate device replacement.
  • Do not use the PressureWire™ X Guidewire in conjunction with atherectomy catheters. It may damage the PressureWire™ X Guidewire.
  • Do not withdraw or manipulate the PressureWire™ X Guidewire with a sharp-edged object. It may result in abrasion of the PressureWire™ X Guidewire coating. When wet, the hydrophilic coating increases the lubricity of the coated surface.
  • Factors that may affect the accuracy of the diagnostic information include, but are not limited to:
    • Improper placement of the aortic pressure sensor.
    • Failure to achieve maximum coronary and myocardial hyperemia during FFR procedures
    • Blood flow affected by the position of interventional devices, such as balloon catheters.
  •  PressureWire™ X Guidewire readings may be affected by defibrillation. Rezero the guidewire after defibrillation use.
  • Do not measure pressure when the PressureWire™ X Guidewire sensor element is in a sharp bend or in contact with atrial or ventricular walls. It might result in pressure artifacts.
  • Do not use the PressureWire™ X Guidewire together with another guidewire, for so-called jailed wire technique, due to difficulty in guidewire withdrawal and possible guidewire entrapment.
  • Avoid abrasion of the distal hydrophilic and proximal PTFE coating regions. Use caution when manipulating, advancing and / or withdrawing these devices through needles, metal cannulas, stents, or other devices with sharp edges, or through tortuous or calcified blood vessels. Manipulation, advancement, and / or withdrawal past sharp or beveled edges may result in destruction and / or separation of the outer coating, which may lead to clinical adverse events, resulting in coating material remaining in the vasculature or device damage. This may result in adverse events requiring additional intervention.
  • The integrity and performance of the device coating can be negatively impacted by preparation with incompatible media or solvents. Please take note of the following important recommendations:
    • Avoid wiping the distal end of the device with dry gauze as this may damage the device coating; refer to Directions for Use for removal / reintroduction instructions.
    • Avoid excessive wiping of the coated device.
    • Avoid using alcohol, antiseptic solutions, or other solvents to pre-treat the device because this may cause unpredictable changes in the coating which could negatively affect the safety and performance of the device.
    • Do not soak the device as it may adversely impact the hydrophilic coating on the device.
  • The PressureWire™ X Guidewire contains parts with > 0.1% w/w concentration of 1-methyl-2-pyrrolidone or NMP, which has shown reproductive toxicity and teratogenicity in animal tests. This device has not been tested in pregnant women or in men intending to father children.
    Effects on the developing fetus have not been studied. In the worst-case scenario, the amount of NMP that may elute out of the PressureWire™ X Guidewire is > 25 times lower than the permissible daily exposure (PDE) by the ICH Q3C (R8) Guidelines for Residual Solvents. Occurrence of this worst-case scenario is highly unlikely, and the expected exposure time of the patient for the FFR procedure is 60 minutes.
    While there is no contraindication, the risks and reproductive effects of use of this device on humans are unknown at this time. It is recommended that the need of the patient and the clinical benefit of FFR be weighed against the risk stated above.
  • One or more components of this device may contain the following substances defined as CMR 1B in a concentration above 0.1% weight by weight: Cobalt; Chemical Abstracts Service (CAS) No. 7440-48-4; EC No. 231-158-0. Current scientific evidence supports that medical devices manufactured from stainless steel alloys containing cobalt do not cause an increased risk of cancer or adverse reproductive effects.
  • The safety and effectiveness of the PressureWire™ X Guidewire has not been established in the pediatric population.
  • Persons with known history of allergies to any of the components of this device listed below may suffer an allergic reaction to this device. Prior to its use on the patient, the patient should be counseled on the material contained in the device, and a thorough history of allergies must be discussed. This device contains:
    • Epoxy adhesive
    • Gold
    • Palladium-iridium alloy
    • Polyethylene glycol
    • Polyimide
    • Polyvinyl pyrrolidone hydrophilic coating
    • Polytetrafluoroethylene coating
    • Silicone
    • Silicon
    • Silicon nitride
    • Stainless steel
    • Tin solder paste
  • Store at room temperature (15°C to 25°C) in a dry and dark place.

MAT-2103599 v4.0